Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
T-Force GREEN: Valbenazine in Pediatric Tourette Syndrome
NCT02679079Phase 2Completed
- Sponsor
- Neurocrine Biosciences
- Start
- Mar 2016
- Primary completion
- Apr 2017
- Modality
- Orthosteric Ligands, Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of valbenazine in Tourette syndrome (TS) (3 arms), sponsored by Neurocrine Biosciences. Primary endpoint: Yale Global Tic Severity Scale Total Tic Score at 6 weeks. Started Mar 2016; status: completed.
02
Drugs
valbenazine
03
Conditions
Tourette syndrome (TS)
Beyond the preview
Go deeper on NCT02679079.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02679079.